So far, the reported correlation between MTA1 overexpression and cancer progression and prognosis includes breast cancer [80–83], colon cancer [63, 84], esophageal cancer [64, 85], lung cancer [86, 87], liver cancer [88, 89], gastric cancer [63], thymoma [90], ovarian cancer [91, 92], nasopharyngeal cancer [93, 94], pancreatic cancer [95, 96], prostate cancer [97, 98], and chorionic carcinoma [99]. This evidence concerns the gene MTA1 and breast carcinoma.